The pharmacotherapy of schizophrenia is currently dominated by atypical antipsychotics that primarily target dopaminergic signalling, the dysregulation of which has long been considered to have a ...

Developed by Karuna Therapeutics, recently acquired by Bristol Myers Squibb, Cobenfy diverges from the industry’s dopamine-dominated approach, targeting muscarinic acetylcholine receptors instead.

Background: Many neuromuscular blockers act as negative allosteric modulators of muscarinic acetylcholine receptors by decreasing affinity and potency of acetylcholine. The neuromuscular blocker ...

Our recent work (McQuail & Burk, 2006) suggests that cholinergic muscarinic receptors, particularly the muscarinic M1 receptor, are important for mediating the effects of the cortical acetylcholine on ...

Our recent work (McQuail & Burk, 2006) suggests that cholinergic muscarinic receptors, particularly the muscarinic M1 receptor, are important for mediating the effects of the cortical acetylcholine on ...

Muscarinic receptors are involved with neurotransmission via acetylcholine and glutamate, and are hypothesised to be dysfunctional in schizophrenia. Most drugs developed to treat schizophrenia to ...

Homatropine is an anticholinergic that inhibits activity of the muscarinic acetylcholine receptor with less potency than atropine. Abuse potential (monitor). Life-threatening respiratory ...